Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment*

Junichi Matsubara‡§¶¶, Masaya Ono‡, Kazufumi Honda‡, Ayako Negishi‡, Hideki Ueno||, Takuji Okusaka‖, Junji Furuse**, Koh Furuta‡‡, Emiko Sugiyama§§, Yoshiro Saito §§, Nahoko Kaniwa§§, Junichi Sawada§§, Ayako Shoji¶¶, Tomohiro Sakuma||, Tsutomu Chiba§, Nagahiro Saijo||||, Setsuo Hirohashi‡, and Tesshi Yamada‡

Although gemcitabine monotherapy is the standard treatment for advanced pancreatic cancer, patient outcome varies significantly, and a considerable number do not benefit adequately. We therefore searched for new biomarkers predictive of overall patient survival. Using LC-MS, we compared the baseline plasma proteome between 29 representative patients with advanced pancreatic cancer who died within 100 days and 31 patients who survived for more than 400 days after receiving at least two cycles of the same gemcitabine monotherapy. Identified biomarker candidates were then challenged in a larger cohort of 304 patients treated with the same protocol using reverse-phase protein microarray. Among a total of 45,277 peptide peaks, we identified 637 peaks whose intensities differed significantly between the two groups (p < 0.001, Welch’s t test). Two MS peaks with the highest statistical significance (p = 2.6 × 10^{-4} and p = 5.0 × 10^{-4}) were revealed to be derived from α1-antitrypsin and α1-antichymotrypsin, respectively. The levels of α1-antitrypsin (p = 8.9 × 10^{-7}) and α1-antichymotrypsin (p = 0.001) were significantly correlated with the overall survival of the 304 patients. We selected α1-antitrypsin (p = 0.0001), leukocyte count (p = 0.066), alkaline phosphatase (p = 8.3 × 10^{-4}), and performance status (p = 0.003) using multivariate Cox regression analysis and constructed a scoring system (nomogram) that was able to identify a group of high risk patients having a short median survival time of 150 days (95% confidence interval, 123–187 days; p = 2.0 × 10^{-15}, log rank test). The accuracy of this model for prognostication was internally validated and showed good calibration and discrimination with a bootstrap-corrected concordance index of 0.672. In conclusion, an increased level of α1-antitrypsin is a biomarker that predicts short overall survival of patients with advanced pancreatic cancer receiving gemcitabine monotherapy. Although an external validation study will be necessary, the current model may be useful for identifying patients unsuitable for the standardized therapy. Molecular & Cellular Proteomics 9:695–704, 2010.

Invasive ductal adenocarcinoma of the pancreas is one of the most aggressive and lethal malignancies (1). It is the fifth leading cause of cancer-related death in Japan and the fourth in the United States, accounting for an estimated >23,000 deaths per year in Japan and >33,000 in the United States (2, 3). Because the majority of patients have distant metastases even at their first presentation (4, 5), the main therapeutic modality for pancreatic cancer is systemic chemotherapy, and gemcitabine monotherapy is the current standard (6). Gemcitabine treatment has significantly improved the median survival time of patients with advanced pancreatic cancer (7). However, the outcome of the treatment varies significantly among individuals, and a considerable portion of patients do not appear to benefit significantly from it. It therefore seems necessary to assess the efficacy and adverse effects of the drug before administration and tailor the treatment accordingly for each person.

We previously identified a predictive biomarker for hematologic toxicity, which is one of the most frequent and potentially life-threatening adverse effects associated with gemcitabine monotherapy (8). As a next step, we performed a large scale proteome analysis in this study to identify biomarkers predictive of patient survival after gemcitabine monotherapy. Several factors and their combinations have been reported to correlate significantly with outcome in patients with advanced pancreatic cancer receiving gemcitabine, such as performance status, metastases, serum albumin, alkaline phosphatase, and peripheral leukocyte count (9–11). Unfortunately, however, the accuracy of survival prediction based on these conventional prognostic factors seems unsatisfactory (9).

In recent years, there has been considerable interest in applying advanced proteomics technologies to the discovery of predictive biomarkers (12, 13). We and others have
successfully applied MALDI MS-based protein profiling techniques for predicting the efficacy of chemoradiotherapy and molecular targeting therapy (14, 15). Two-dimensional image converted analysis of liquid chromatography and mass spectrometry (2DICAL)\(^1\) is a new LC-MS-based proteomics platform that was developed in our laboratory (16). 2DICAL can quantify protein content accurately across a theoretically unlimited number of samples without isotope labeling and thus has considerable advantages over conventional LC-MS-based methods for clinical studies (17). The predictive biomarker protein for hematologic toxicity described above was identified using 2DICAL (8).

It has been generally accepted that tumor responses do not always correlate with the outcome of patients (10, 18, 19). The rates of complete and partial responses (Response Evaluation Criteria in Solid Tumors guideline) to gemcitabine monotherapy were assessed using Wilcoxon test. The results are presented in Table I.

### Table I

**Clinical and laboratory data of patients with short term or long term survival**

Survival time was calculated from the date of starting gemcitabine therapy until the date of death from cancer. Wilcoxon test was applied to assess differences in values. 5-FU, 5-fluorouracil; LAPC, locally advanced pancreatic cancer; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; \(C_{\text{max}}\), peak concentration; AUC, area under the curve.

|                      | Short term survivor (<100 days) | Long term survivor (>400 days) | \(p\)  |
|----------------------|---------------------------------|---------------------------------|-------|
| No. of patients      | 29                              | 31                              | 0.361* |
| Sex (no. of patients)|                                 |                                 |       |
| Male                 | 21                              | 19                              |       |
| Female               | 8                               | 12                              |       |
| Age, mean (S.D.) (years) | 63 (7)                          | 67 (8)                          | 0.123  |
| ECOG performance status (no. of patients) | 8                               | 12                              | 0.008* |
| 0                    | 8                               | 18                              |       |
| 1                    | 18                              | 11                              |       |
| 2                    | 3                               | 0                               |       |
| Body surface area, mean (S.D.) (m\(^2\)) | 1.59 (0.17)                      | 1.54 (0.15)                      | 0.333  |
| Prior therapy        |                                 |                                 | 0.438* |
| None                 | 27                              | 27                              |       |
| Chemoradiotherapy using 5-FU for LAPC | 2                               | 4                               |       |
| Clinical stage\(^b\) |                                 |                                 | 0.697* |
| IVA                  | 2                               | 3                               |       |
| IVB                  | 27                              | 28                              |       |
| Subsequent line chemotherapy after gemcitabine | 0.045*                          |                                 |       |
| None                 | 29                              | 27                              |       |
| Yes                  | 0                               | 4                               |       |
| Leukocytes, mean (S.D.) (\(\times 10^3/\text{mm}^3\)) | 7.6 (3.6)                      | 5.2 (1.3)                      | 0.002  |
| Platelets, mean (S.D.) (\(\times 10^4/\text{mm}^3\)) | 24.5 (7.6)                      | 20.2 (4.6)                      | 0.020  |
| Hemoglobin, mean (S.D.) (g/dl) | 11.7 (1.6)                      | 11.7 (1.5)                      | 0.491  |
| Albumin, mean (S.D.) (g/dl) | 3.4 (0.4)                      | 3.7 (0.3)                      | 0.014  |
| Creatinine, mean (S.D.) (mg/dl) | 0.70 (0.23)                      | 0.68 (0.23)                      | 0.726  |
| AST, mean (S.D.) (IU/liter) | 40 (25)                      | 26 (15)                      | 0.010  |
| ALT, mean (S.D.) (IU/liter) | 51 (44)                      | 27 (19)                      | 0.037  |
| ALP, mean (S.D.) (units/liter) | 728 (632)                      | 337 (160)                      | 0.026  |
| Pharmacokinetic parameters of gemcitabine |                                 |                                 |       |
| \(C_{\text{max}}\), mean (S.D.) (\(\mu\text{g/ml}\)) | 24.02 (7.52)                      | 24.91 (6.22)                      | 0.610  |
| AUC, mean (S.D.) (h\(\cdot\mu\text{g/ml}) | 10.24 (2.83)                      | 10.75 (2.32)                      | 0.270  |
| \(\alpha_1\)-Antitrypsin,\(^c\) mean (S.D.) | 64.6 (66.8)                      | 16.9 (7.9)                      | 0.0003 |
| \(\alpha_1\)-Antichymotrypsin,\(^c\) mean (S.D.) | 706.4 (416.0)                     | 389.0 (216.5)                     | 0.0005 |
| Tumor response\(^d\) |                                 |                                 |       |
| Complete response     | 0                               | 0                               | <0.0001* |
| Partial response      | 0                               | 1                               |       |
| Stable disease        | 2                               | 22                              |       |
| Progressive disease   | 24                              | 0                               |       |
| Not evaluable         | 3                               | 8                               |       |

\(^a\) Calculated by \(\chi^2\) test.

\(^b\) According to Ref. 23.

\(^c\) Intensity of the corresponding peak measured by quantitative mass spectrometry.

\(^d\) Evaluated after the first two cycles of gemcitabine monotherapy.

---

\(1\) The abbreviations used are: 2DICAL, two-dimensional image converted analysis of liquid chromatography and mass spectrometry; AIC, Akaike’s information criterion; CC, correlation coefficient; CI, confidence interval; CV, coefficient of variance; ECOG, Eastern Cooperative Oncology Group; NCC, National Cancer Center; ID, identification; FDR, false discovery rate.
therapy are limited to ~10% (20–22), and the majority of pancreatic cancers do not show significant tumor regression. Given that the ultimate goal of gemcitabine therapy for pancreatic cancer is to achieve prolonged survival, it would be desirable to stratify patients according to survival rather than tumor response (9). In the present study, using 2DICAL, we compared the base-line plasma proteome of two extreme populations of patients who had shown distinct clinical courses after identical gemcitabine treatment.

**EXPERIMENTAL PROCEDURES**

**Patients**—Samples were collected from a total of 304 patients who had all been included in our previous study (8). All patients had metastatic (stage IVb; n = 285) or locally advanced (stage IVa; n = 19) (23) histologically or cytologically proven pancreatic ductal adenocarcinoma and had received at least two cycles of gemcitabine mono-therapy (1,000 mg/m² intravenously over 30 min on days 1, 8, and 15 of a 28-day cycle). Two hundred eighty-one patients (92%) received gemcitabine as a first line therapy (supplemental Table S1).

Two hundred sixty-two patients (86%) were treated consecutively at the National Cancer Center (NCC) Hospital (Tokyo, Japan) between September 2002 and June 2007, and 42 patients (14%) were treated consecutively at the NCC Hospital East (Kashiwa, Japan) between September 2002 and July 2004. Survival times were determined as of May 2008. During this period, 248 patients (82%) died, and 56 patients (18%) were censored. Tumor response was evaluated after the first two cycles of gemcitabine using the Response Evaluation Criteria in Solid Tumors guideline.

**Sample Preparation**—Blood was collected before the first administration of gemcitabine. Plasma or serum was separated by centrifugation at 1,050 × g for 10 min at 4 °C and frozen until analysis as reported previously (8, 24). Macroscopically hemolyzed samples were excluded from the current analysis. Two hundred fifty-two plasma samples (83%) were collected from the NCC Hospital and Hospital East, and 52 serum samples (17%) were collected from the NCC Hospital. Written informed consent was obtained from all patients before blood sampling. The protocol of this retrospective study was reviewed and approved by the institutional ethics committee boards of the NCC (Tokyo, Japan) and the National Institute of Health Sciences (Tokyo, Japan).

**LC-MS**—Samples were blinded, randomized, and passed through an IgY-12 High Capacity Spin Column (Beckman Coulter, Fullerton, CA) in accordance with the manufacturer’s instructions. The flow-through portion was digested with sequencing grade modified trypsin (Promega, Madison, WI) and analyzed in triplicate using a nanoflow high performance LC system (NanoFrontier nLC, Hitachi High Technologies, Tokyo, Japan) connected to an electrospray ionization quadrupole time-of-flight mass spectrometer (Q-Tof Ultima, Waters, Milford, MA). LC-MS run order was also randomized to eliminate any potential bias.

MS peaks were detected, normalized, and quantified using the in-house 2DICAL software package as described previously (16). A serial identification (ID) number was applied to each of the MS peaks detected (1–45,277). The stability of LC-MS was monitored by calculating the correlation coefficient (CC) and coefficient of variance (CV) of every triplicate measurement. The mean CC and CV ± S.D. for all 45,277 peaks observed in the 60 triplicate runs were as high as 0.970 ± 0.022 and as low as 0.056 ± 0.017, respectively.

**Protein Identification by MS/MS**—Peak lists were generated using the Mass Navigator software package (version 1.2) (Mitsui Knowledge Industry, Tokyo, Japan) and searched against the NCBIr database (downloaded on May 20, 2008) using the Mascot software package (version 2.2.1) (Matrix Science, London, UK). The search parameters used were as follows. A database of human proteins was selected.
Reverse-phase Protein Microarray—Samples were serially diluted 1:500, 1:1,000, 1:2,000, and 1:4,000 using a Biomek 2000 Laboratory Automation Robot (Beckman Coulter) and randomly plotted onto ProteoChip/H23006 glass slides (Proteogen, Seoul, Korea) in quadruplicate in a 6,144-spot/slide format using a Protein Microarrayer Robot (Kaken Geneqs Inc., Matsudo, Japan). The spotted slides were incubated overnight with the same primary antibodies as those used in Western blotting. The slides were incubated with biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA) and subsequently with streptavidin-horseradish peroxidase conjugate (GE Healthcare). The peroxidase activity was detected using the Tyramide Signal Amplification (TSA/H23006) Cyanine 5 System (PerkinElmer Life Sciences). The slides were counterstained with Alexa Fluor/H23006 546-labeled goat anti-human IgG (Invitrogen) (spotting control). The stained slides were scanned on a microarray scanner (InnoScan/H23006 700AL, Innopsys, Carbone, France). Fluorescence intensity, determined as the mean net value of quadruplicate samples, was determined using the Mapix/H23006 software package (Innopsys). All determined intensity values were transformed into logarithmic variables.

The reproducibility of reverse-phase protein microarray assay was revealed by repeating the same experiment. A plasma sample was serially diluted within a range of 1,024–16,384-fold. Each diluted sample was spotted in quadruplicate onto glass slides and blotted with anti-α1-antitrypsin antibody. In a representative quality control experiment, the CC value was 0.977 between days, and the median CV was 0.026 among quadruplicate samples.

Statistical Analysis—Overall survival time was defined as the period from the date of starting gemcitabine monotherapy until the date of death from any cause or until the date of the last follow-up at which point the data were censored. We used the Kaplan-Meier method to plot overall survival curves. Statistical significance of intergroup differences was assessed with Welch’s t test, Wilcoxon test, χ2 test, or log rank test as appropriate. The maximally selected statistics (27) using the fitness of univariate Cox model (log likelihood) was used to determine which level (optimal cutoff point) of each factor best segregated patients in terms of survival.

Multivariate regression analysis was performed using ordinal Cox regression modeling. Factors included in the prediction model were selected with a forward stepwise selection procedure using Akaike’s information criterion (AIC), and the result was confirmed using a backward stepwise procedure. The significance of differences between models with and without α1-antitrypsin was assessed with the likelihood ratio test. The survival prediction model was internally validated by measuring both discrimination and calibration (28). Discrimination was evaluated using the concordance index, which is similar in concept to the area under the receiver operating characteristic curve. Calibration was evaluated with a calibration curve whereby patients are categorized by predicted survival and then
plotted as actual versus predicted survival. Both discrimination and calibration were evaluated for the whole study cohort using 200 cycles of bootstrap resampling. Statistical analyses were performed using the open source statistical language R (version 2.7.0) with the optional module Design package.

RESULTS

The median survival estimate for the present study was 236 days (95% CI, 216–254 days), which is comparable to those of previous large scale studies (10, 22). To identify a prognostic factor in patients with advanced pancreatic cancer, we compared the base-line plasma proteome between 29 patients showing short term survival (<100 days) and 31 patients showing long term survival (>400 days) using 2DICAL. There was no significant difference in age, sex, body surface area, prior therapy, clinical stage, or gemcitabine pharmacokinetics (24) (Table I) between the two groups, but the patients with short term survival had significantly poorer base-line conditions such as liver function and Eastern Cooperative Oncology Group (ECOG) performance status than those with long term survival (Table I).

Among a total of 45,277 independent MS peaks detected within the range 250–1,600 m/z and within the time range of 20–70 min, we found that the mean intensity of triplicates differed significantly for 637 peaks ($p < 0.001$, Welch’s t test). Fig. 1A is a representative two-dimensional view of all the MS peaks displayed with $m/z$ along the x axis and the retention time of LC along the y axis. The 637 MS peaks whose expression differed significantly between patients with short term and long term survival are highlighted in red.

MS peaks that were increased in patients with short term survival with the highest statistical significance ($p = 2.57 \times 10^{-4}$) (Fig. 1B) matched the amino acid sequences of the $\alpha_1$-antitrypsin (AAT) gene product (supplemental Fig. S1A). The MS peak with the second highest statistical significance ($p = 5.03 \times 10^{-4}$) was revealed to be derived from the $\alpha_1$-antichymotrypsin (AACT) gene product (supplemental Fig. S1B). We calculated the false discovery rate (FDR) (29) and confirmed the significance of these MS peaks (FDR $= 0.0327$ for $\alpha_1$-antitrypsin and FDR = 0.0428 for $\alpha_1$-antichymotrypsin).

Fig. 2A shows the distribution of the two peaks (ID 1740 (at 508 $m/z$ and 48.9 min; $\alpha_1$-antitrypsin) and ID 11165 (at 713 $m/z$ and 41.5 min; $\alpha_1$-antichymotrypsin)) in patients with short term (red) and long term survival (blue). The differential expression and identification of $\alpha_1$-antitrypsin and $\alpha_1$-antichymotrypsin were confirmed by denaturing SDS-PAGE and immunoblotting (Fig. 2B).

Correlation of $\alpha_1$-Antitrypsin and $\alpha_1$-Antichymotrypsin with Overall Survival—The relative levels of $\alpha_1$-antitrypsin and $\alpha_1$-antichymotrypsin in plasma or serum samples obtained from 304 patients with advanced pancreatic cancer prior to gemcitabine treatment (including 60 patients used in 2DICAL)
were measured using reverse-phase protein microarrays (Fig. 3). Quadruplicate spots for representative patients with high and low levels of α₁-antitrypsin are shown in Fig. 3. There were no differences between plasma (n = 252) and serum (n = 52) with regard to the levels of α₁-antitrypsin and α₁-antichymotrypsin (plasma versus serum (mean ± S.D.): α₁-antitrypsin, 2.10 ± 0.19 versus 2.16 ± 0.16, p = 0.06; α₁-antichymotrypsin, 4.44 ± 0.10 versus 4.45 ± 0.08, p = 0.67).

Although the levels of α₁-antitrypsin and α₁-antichymotrypsin were not mutually correlated (Pearson’s r = 0.274), either level showed a significant correlation with overall survival (Table II). When the optimal cutoff value was determined by the median survival time of patients with high levels of α₁-antitrypsin (>2.09 arbitrary units) was significantly shorter than that of patients with low levels (<=2.09) (201 days (95% CI, 176–219 days) versus 327 days (95% CI, 271–439 days), log rank = 2.26 × 10⁻⁹; Fig. 4A). Similarly, the median survival time was significantly shorter in patients with α₁-antichymotrypsin levels of >4.41 (211 days (95% CI, 193 to 235 days)) than in those with levels of ≤4.41 (327 days (95% CI, 255–416 days)) (p = 2.02 × 10⁻⁴; Fig. 4B). Even when the 60 patients used for 2DICAL were excluded, the differences in survival separated by α₁-antitrypsin and α₁-antichymotrypsin levels were still significant (supplemental Fig. S2, A and B). However, the level of either α₁-antitrypsin or α₁-antichymotrypsin was not associated with tumor response (Spearman’s p = 0.090 and p = 0.017, respectively). The increased level of α₁-antitrypsin in 58 patients who subsequently developed progressive diseases was statistically significant (p = 0.020; supplemental Fig. S3) but quite modest, confirming that it is not a predictive biomarker of tumor response.

**Construction and Validation of Model Predicting Overall Survival Time**—Univariate Cox regression analysis revealed that ECOG performance status and laboratory values including leukocyte count, albumin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, α₁-antitrypsin, and α₁-antichymotrypsin were correlated with overall survival of the 304 patients (p < 0.05; Table II). Because none of the parameters were able to predict survival outcome satisfactorily when used individually (data not shown), we attempted to construct a multivariate predictive model for estimation of overall survival. We searched for parameters using a forward stepwise selection procedure by AIC from all the clinical and laboratory data listed in Table II (available for all 304 cases) and found that a combination of α₁-antitrypsin, alkaline phosphatase, leukocyte count, and ECOG performance status provided the lowest AIC value. We also searched for parameters using a backward elimination algorithm and found that this identified the same combination of factors as that selected by a forward stepwise procedure. The base-line α₁-antitrypsin level was the second most significant contributor to the model (Table II). The prediction model using this combination of parameters was significantly compromised when the level of α₁-antitrypsin was excluded (Δχ² = 14.12, df = 1, p = 0.0002, likelihood ratio test).

Based on the results of multivariate Cox regression analysis, we constructed a scoring system (nomogram) in which the values of the four parameters (α₁-antitrypsin, alkaline phosphatase, leukocyte count, and ECOG performance status) were integrated into a single score (total point) to estimate the probability of survival. The nomogram is based on the hazard ratios of the four parameters, which were calculated using the Cox regression model. The hazard ratio for each parameter is given by (Hazard ratio = exp(β)), where β is the coefficient associated with the parameter in the Cox regression model. The total point for each patient is calculated by summing the products of the hazard ratio and the value of the parameter. The probability of survival is then estimated by interpolating the total point on the nomogram. The nomogram is easy to use and can be applied to any patient with pancreatic cancer to predict their survival probability.
the survival outcome (Fig. 5A). The accuracy of the nomogram for prognostication was internally validated. The bootstrap-corrected concordance index was 0.672, and the calibration curve demonstrated good agreement between the predicted and observed outcomes (Fig. 5B). It was possible to estimate high risk patients by calculating the total points using the nomogram. The median survival time was 150 days (95% CI, 123–187 days) for patients with a total point score of ≥94 (n = 98) and 282 days (95% CI, 255–328 days) for patients with a score of ≤94 (n = 206), and the difference was significant (p = 2.00 × 10^{-15}, log rank test; Fig. 5C). Even when the 60 patients used for 2DICAL analyses were excluded from the calculations, the difference was still significant (p = 5.23 × 10^{-10}, supplemental Fig. S2C). The median survival time was 171 days (95% CI, 147–205 days) for patients with a score of ≥92 (n = 83) and 270 days (95% CI, 243–299 days) for patients with a score of ≤92 (n = 161). The cutoff value that optimally segregated patients into subgroups with a poor and good prognosis was determined by using the maximally selected statistics.

DISCUSSION

Currently, no diagnostic tool has been established for stratifying patients with advanced pancreatic cancer according to their likelihood of obtaining a survival benefit from gemcitabine treatment. Because some high risk patients may achieve prolonged survival through modification (or even withdrawal) of therapeutic protocols, a diagnostic method that can accurately identify such patients is necessary. We first compared the plasma proteome of two groups of patients who showed distinct clinical courses after receiving the same gemcitabine protocol (Fig. 1) and found that individuals who showed poor clinical courses had shown high baseline levels of plasma α₁-antitrypsin and α₁-antichymotrypsin (Figs. 1B and 2A). α₁-Antitrypsin is an abundant plasma protein that usually cannot be measured by MS. However, antibody-based protein depletion (30) allowed us to accentuate the differences in α₁-antitrypsin levels.

The results obtained by 2DICAL were then validated in a 5-fold larger cohort using a different methodology: high density reverse-phase protein microarray (Figs. 3 and 4 and Table II). Reverse-phase protein microarray is an emerging proteomics technology capable of validating new biomarkers because of its overwhelmingly high throughput (31, 32). Furthermore, reverse-phase protein microarrays require significantly smaller amounts of clinical samples for quantification than established clinical tests, such as ELISA. The prognostic significance of α₁-antitrypsin was further supported by multivariate survival analysis with stepwise covariate selection. The level of α₁-antitrypsin was selected as the second most significant factor following alkaline phosphatase (Table II), but α₁-antichymotrypsin was not selected. To derive clinical applicability from the above findings, we constructed a model (nomogram) including α₁-antitrypsin to estimate the survival period of pancreatic cancer patients (Fig. 5A), and its significance was internally validated (Fig. 5B). One previous study has demonstrated a correlation between an increased serum level of α₁-antitrypsin and short survival in patients treated surgically for pancreatic cancer (33). Although the number of cases examined was small (n = 44), the results support our present findings.

α₁-Antitrypsin and α₁-antichymotrypsin are members of the serine protease inhibitor (serpin) superfamily that plays key roles in the regulation of inflammatory cascades (34, 35). α₁-Antitrypsin and α₁-antichymotrypsin interact mainly with neutrophil elastase and neutrophil cathepsin G, respectively, and inhibit their protease activities (36). A protease-to-protease inhibitor imbalance in patients with genetic α₁-antitrypsin deficiency is reported to confer a higher risk of chronic pancreatitis (37). However, the serum level of α₁-antitrypsin in patients with pancreatic cancer varied significantly from case to case, and its clinical significance has remained unclear. We showed that increased concentrations of α₁-antitrypsin and α₁-antichymotrypsin in plasma/serum correlated with poor
survival, indicating that patients with poor outcomes have lower base-line protease activities than those with favorable outcomes. How such a protease imbalance affects the progression of pancreatic cancer awaits further clarification in future studies.

In conclusion, we identified a prognostic biomarker potentially useful for selecting high risk patients with advanced pancreatic cancer who are unlikely to gain adequate survival benefit from the standard treatment. This may be of great clinical importance, especially when an alternative therapeutic option becomes available for patients with advanced pancreatic cancer in the future. However, the level of $\alpha_1$-antitrypsin was not significantly correlated with the efficacy of gemcitabine, indicating that it may reflect the natural course of pancreatic cancer irrespective of treatment.

Therefore, an independent prospective validation study will be definitely necessary to confirm the universality of the present findings. The absolute concentration of $\alpha_1$-antitrypsin can be measured by nephelometry, but this measurement requires a larger sample volume than reverse-phase microarrays and for this reason could not be performed in this study. While bearing all these limitations in mind, the present findings may not only help to stratify patients with pancreatic cancer but also provide novel insights into the molecular mechanisms behind the malignant progression of this neoplasm, possibly leading to the development of novel therapeutic strategies.

Acknowledgments—We thank Ayako Igarashi, Tomoko Umaki, and Yuka Nakamura for technical assistance.

Fig. 5. A, nomogram for estimating the probability (Prob) of survival 6, 12, and 24 months (mo) after gemcitabine treatment. See supplemental Fig. S4 and its legend for details of usage. B, calibration curve demonstrating the correlation between predicted and actual survival at 12 months after gemcitabine treatment. Bars represent 95% CI. C, Kaplan-Meier plots of overall survival according to total points. ALP, alkaline phosphatase.
REFERENCES

1. Honda, K., Hayashida, Y., Umati, T., Okusaka, T., Kosuge, T., Kikuchi, S., Endo, M., Tsuchida, A., Aoki, T., Ito, T., Moriyasu, F., Hirohashi, S., and Yamada, T. (2005) Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 65, 10613–10622

2. American Cancer Society (2007) Cancer Facts and Figures 2007, pp. 16–17. American Cancer Society, Atlanta, GA

3. Ministry of Health, Labour and Welfare (2009) Japanese Government: Vital Statistics of Japan, Ministry of Health, Labour and Welfare, Tokyo

4. Rosewicz, S., and Wiedenmann, B. (1997) Pancreatic carcinoma. Lancet 349, 485–489

5. Nito, J., Grossbard, M. L., and Kozuch, P. (2008) Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13, 562–576

6. National Comprehensive Cancer Network (2009) Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, Vol. 1, National Comprehensive Cancer Network, Fort Worth, PA

7. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R., K. Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403–2413

8. Matsubara, J., Ono, M., Negishi, A., Ueno, H., Okusaka, T., Furuse, J., Furuta, K., Sugiyama, E., Saito, Y., Kaniwa, N., Sawada, J., Honda, K., Sakuma, T., Chiba, T., Saji, N., Hirohashi, S., and Yamada, T. (2009) Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J. Clin. Oncol. 27, 2261–2268

9. Stockton, D. D., Hassan, A. B., Altman, D. G., Billingham, L. J., Brannham, S. R., Johnson, P. J., and Freemantle, N. (2008) Modelling prognostic factors in advanced pancreatic cancer. Br. J. Cancer 99, 883–893

10. Louvet, C., Labianca, R., Hammel, P., Ledo, G., Zampino, M. G., Grillet, P., Zampino, M. G., Andre´, T., Schiller, J. H., Hirohashi, S., and Yamada, T. (2009) Prediction of survival probability for pancreatic cancer patients: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 23, 3509–3516

11. Storniolo, A. M., Enas, N. H., Brown, C. A., Vo, M., Rothenberg, M. L., and Schilsky, R. (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85, 1261–1268

12. Hanash, S. (2003) Disease proteomics. Nature 422, 226–232

13. Yamaguchi, U., Nakayama, R., Honda, K., Ichikawa, H., Hasegawa, T., Shitsuhige, M., Ono, M., Shoji, A., Sakuma, T., Kuwabara, H., Shimada, Y., Sasako, M., Shimoda, T., Kawai, A., Hirohashi, S., and Yamada, T. (2006) Distinct gene expression-defined classes of gastrointestinal stromal tumor. J. Clin. Oncol. 24, 1100–1108

14. Hayashida, Y., Honda, K., Osaka, Y., Hara, T., Umati, T., Tsuchida, A., Aoki, T., Hirohashi, S., and Yamada, T. (2005) Possible prediction of chemo-radiosensitivity of esophageal cancer by serum protein profiling. Clin. Cancer Res. 11, 8042–8047

15. Taguchi, F., Solomon, B., Gregorc, V., Roder, H., Gray, R., Kasahara, K., Nishio, M., Brahmer, J., Spreda, A., Ludovini, V., Massion, P. P., Dziadzio, S., Schiller, J., Grigorieva, J., Tsykin, M., Hunsucker, S. W., Caprioli, R., Duncan, M. W., Hirsch, F. R., Bunn, P. A., Jr., and Carbone, D. P. (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multichort cross-institutional study. J. Natl. Cancer Inst. 99, 838–846

16. Ono, M., Shishigahie, M., Honda, K., Isobe, T., Kuwabara, H., Matsuzuki, H., Hirohashi, S., and Yamada, T. (2006) Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol. Cell. Proteomics 5, 1338–1347

17. Negishi, A., Ono, M., Handa, Y., Kato, H., Yamashita, K., Honda, K., Shishigahie, M., Satow, R., Sakuma, T., Kuwabara, H., Omura, K., Hirohashi, S., and Yamada, T. (2009) Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci. 100, 514–519

18. Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jr., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., and Miller, L. L. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22, 3776–3783

19. Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humbert, Y., Gill, S., Van Laethem, J. L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., and Moore, M. J. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231–2241

20. Heinemann, H., Schiller, J., Hunsucker, S., Grigorieva, J., Tsypin, M., Fenger, H., Oespel, J., von Hoff, D. D. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1980–1986

21. Heinemann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schiller, J., Saletti, P., Bauer, J., Figi, A., Pestalozzi, B., Kohn, M. A., Minchina, W., Stermer, S. M., Tamas, K., Konek, G. K., Koeberle, D., Cina, S., Bernhard, J., Dietrich, D., and Scheithauer, W. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swisson Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 25, 2212–2217

22. Japanese Pancreas Society (ed) (2002) General Rules for the Study of Pancreatic Cancer, 5th Ed., Kanehara, Tokyo

23. Sugiya, M., Kaniwa, N., Kim, S. R., Ikura-Hanajiri, R., Hasegawa, R., Maekawa, K., Saito, Y., Ozawa, S., Sawada, J., Kamatani, N., Furuse, J., Ishii, H., Yoshida, T., Ueno, H., Okusaka, T., and Saji, N. (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a genetic polymorphism in 1000 cancer patients. Biometrics 64, 1263–1269

24. Wang, S. J., Fuller, C. D., Kim, J. S., Sittig, D. F., Thomas, C. R., Jr., and Ravid, P. S. (2008) Prediction model for estimating the survival benefit of adjuvant radiotherapy for bladder cancer. J. Clin. Oncol. 26, 2112–2117

25. Storey, J. D., and Tibshirani, R. (2003) Statistical significance for genome-wide studies. Proc. Natl. Acad. Sci. U.S.A. 100, 9440–9445

26. Huang, L., Harvie, G., Feltison, J. S., Gramatikoff, K., Herold, D. A., Allen, D. L., Amunngama, R., Hagler, R. A., Pisano, M. R., Zhang, W. W., and Fang, X. (2005) Immunocaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 5, 3314–3328
Whitcomb, D. C., and Logsdon, C. D. (2008) Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19–9 levels in pancreatic cancer. Proteomics 8, 3051–3060
32. Wulfkuhle, J. D., Liotta, L. A., and Petricoin, E. F. (2003) Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3, 267–275
33. Trichopoulos, D., Tzonou, A., Kalapothaki, V., Sparos, L., Kremastinou, T., and Skoutari, M. (1990) Alpha 1-antitrypsin and survival in pancreatic cancer. Int. J. Cancer 45, 685–686
34. Lomas, D. A., and Mahadeva, R. (2002) Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J. Clin. Investig. 110, 1585–1590
35. Stoller, J. K., and Aboussouan, L. S. (2005) Alpha1-antitrypsin deficiency. Lancet 365, 2225–2236
36. Beatty, K., Bieth, J., and Travis, J. (1980) Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J. Biol. Chem. 255, 3931–3934
37. Rabassa, A. A., Schwartz, M. R., and Ertan, A. (1995) Alpha 1-antitrypsin deficiency and chronic pancreatitis. Dig. Dis. Sci. 40, 1997–2001